AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$TEVA

What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call

Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP gross margin of 58.7%, up 2.45% from last year. Free cash flow was $495M. The company raised full-year revenue guidance to $16.7B-$17B. Teva expects flat generics revenue in 2026, excluding generic REVLIMID, and anticipates biosimilar sales to hit $800M, a year ahead of schedule.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 10:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The earnings beat and guidance lift are likely to boost TEVA's share price, while the decline in generic revenue and regulatory uncertainties provide downside considerations.

02

Market read

Teva's improved margins, debt repayment, and upgraded guidance present a bullish catalyst for the stock, offset by mixed segment performance.

03

What to watch

Potential headwinds from the Inflation Reduction Act and the discontinued emrusolmin study could dampen upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Teva Pharmaceutical Industries (NYSE:TEVA) reported its Q3 earnings call, highlighting margin expansion, debt reduction, and upgraded full‑year guidance.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva disclosed Q3 non‑GAAP gross margin, free cash flow, debt repayment, and raised full‑year guidance on revenue, operating income, EBITDA, EPS and free‑cash‑flow.

Expected impact

potential upside as market prices in stronger earnings and credit profile

Evidence & confidence

Guidance lifts across multiple metrics and achievement of investment‑grade rating are material, new information.

Market effects

Sector

Generics and biosimilars sector may see renewed investor interest from Teva's guidance lift.

Regional

European credit markets could benefit from Teva's investment‑grade rating and debt repayment.

Global

Improved credit profile may affect global pharma credit spreads.

Counterpoint

What could challenge this read

Guidance raises may already be priced in; focus on the 16% decline in generic revenue and pending regulatory risks.

Key entities

  • Executive
    Eli Kalif

    Chief Financial Officer who presented the financial results.

  • Executive
    Francis

    Company spokesperson discussing pipeline and generics performance.

Read at source← All news

StoryTeva posts Q3 2026 earnings, raises full‑year outlook and announces FDA approval for WELTRUZA

Also covered by

6 outlets

Related articles

NOV 4
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com2 min
NOV 4
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com6 min
NOV 3
$TEVAHighAI 8/10

Teva (TEVA) Q3 2026 Earnings Call Transcript

Teva (TEVA) reported Q3 2026 earnings, highlighting a 2% revenue decline but a 58.7% gross margin. Key products like AUSTEDO, UZEDY, and AJOVY showed strong growth, with UZEDY up 96%. The company discontinued a phase II study for emrusolmin and acquired BXCL501 to strengthen its neuroscience portfolio. Teva achieved investment-grade status and refinanced $4.9 billion in senior notes. The company expects peak sales of $1.5B-$2B for UZEDY and WELTRUZA.

finance.yahoo.com2 min
NOV 3
$TEVAHighAI 9/10

Teva Q3 2026 slides: biopharma shift lifts margins to 58.7%

Teva Pharmaceuticals (NYSE:TEVA) reported Q3 2026 revenues of $4.4B and adjusted EPS of $0.86, beating estimates. Gross margin rose to 58.7% due to a shift toward biopharma. Key products like AUSTEDO, UZEDY, and AJOVY drove growth. The company raised full-year guidance and announced FDA approval for WELTRUZA, a new schizophrenia treatment.

investing.com3 min
NOV 3
$TEVAMed

Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars

Teva Pharmaceuticals and Samsung Bioepis agreed to license and commercialize two FDA-approved biosimilars in the U.S. Teva will handle sales, with Samsung retaining manufacturing. The deal includes upfront payments, milestones, and profit sharing. Closing is expected by the end of 2026, with rights to etanercept-ykro transferring at that time and infliximab-abda in Q3 2027.

pharmexec.com3 min